Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer.

H. Fensterer,Carmen Schade-Brittinger,H. Mueller,B. Schupfner,J. Fass,U. Lindig,U. Settmacher,Matthias Ebert,M. Kornmann,Ralf-Dieter Hofheinz,Esther Endlicher,C Brendel,Peter J. Barth,Detlef K. Bartsch,Thomas Mathias Gress,Arbeitsgemeinschaft Internistische Onkologie

Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer.

2011

H. Fensterer
Carmen Schade-Brittinger
H. Mueller
B. Schupfner
J. Fass
U. Lindig
U. Settmacher
Matthias Ebert
M. Kornmann
Ralf-Dieter Hofheinz
Esther Endlicher
C Brendel
Peter J. Barth
Detlef K. Bartsch
Thomas Mathias Gress
Arbeitsgemeinschaft Internistische Onkologie

4039 Background: Chemotherapy with gemcitabine is the standard adjuvant or additional treatment in R0- or R1-resected pancreatic cancer. Adding cetuximab is suggested to improve the outcome of thes...

Keywords:

Adjuvant therapy
Cetuximab
Cancer research
Physical therapy
Pancreatic cancer
Gemcitabine
Oncology
Medicine
Internal medicine
Adjuvant
in patient
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations